Truist Financial Issues Pessimistic Forecast for GoodRx (NASDAQ:GDRX) Stock Price

GoodRx (NASDAQ:GDRX - Free Report) had its price objective decreased by Truist Financial from $6.50 to $5.50 in a research report released on Thursday morning,Benzinga reports. Truist Financial currently has a hold rating on the stock.

Several other research firms have also recently weighed in on GDRX. Citigroup lowered their price objective on shares of GoodRx from $7.00 to $6.25 and set a "buy" rating on the stock in a research report on Friday, January 10th. KeyCorp lowered their target price on GoodRx from $7.00 to $6.00 and set an "overweight" rating on the stock in a research note on Wednesday, January 8th. Wells Fargo & Company reduced their price target on shares of GoodRx from $9.00 to $8.00 and set an "overweight" rating for the company in a research report on Friday, February 28th. Finally, Morgan Stanley cut their target price on shares of GoodRx from $7.00 to $6.00 and set an "equal weight" rating for the company in a research report on Tuesday, December 17th. Four analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $7.93.

GoodRx Trading Up 0.2 %

Shares of NASDAQ GDRX traded up $0.01 during mid-day trading on Thursday, hitting $4.50. 404,288 shares of the company traded hands, compared to its average volume of 1,454,246. The business has a 50 day moving average of $4.65 and a two-hundred day moving average of $5.04. The stock has a market capitalization of $1.73 billion, a price-to-earnings ratio of -150.00, a PEG ratio of 2.46 and a beta of 1.25. GoodRx has a 1 year low of $3.82 and a 1 year high of $9.26. The company has a quick ratio of 5.48, a current ratio of 5.48 and a debt-to-equity ratio of 0.70.

Remove Ads

Institutional Investors Weigh In On GoodRx

A number of large investors have recently added to or reduced their stakes in the stock. National Bank of Canada FI boosted its holdings in shares of GoodRx by 34.9% during the 4th quarter. National Bank of Canada FI now owns 8,308 shares of the company's stock worth $39,000 after buying an additional 2,151 shares during the period. EP Wealth Advisors LLC acquired a new position in GoodRx during the 3rd quarter worth $73,000. RPO LLC bought a new stake in GoodRx during the fourth quarter valued at about $52,000. Versor Investments LP acquired a new stake in shares of GoodRx in the fourth quarter valued at about $54,000. Finally, Verus Capital Partners LLC acquired a new position in shares of GoodRx during the 4th quarter worth about $55,000. Institutional investors own 63.77% of the company's stock.

About GoodRx

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.